The mechanism by which PAI-1R reduces proteinuria has not been previously explored. r What is the main finding and its importance?
Introduction
Diabetes is the leading cause of end-stage renal disease, and almost half of new end-stage renal disease patients have diabetes (Molitch et al. 2004) . Despite the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (Brenner et al. 2001; Parving et al. 2001) , progression of diabetic nephropathy is common. Hence, it is important to identify other interventions that might retard the progression of diabetic nephropathy.
Recently, plasminogen activator inhibitor type 1 (PAI-1) has emerged as a powerful fibrogenic mediator in kidney diseases, including diabetic nephropathy (Eddy & Fogo, 2006; Brown, 2010; Ghosh & Vaughan, 2012) . Enhanced glomerular expression of PAI-1 has been reported in both human and animal models of diabetes (Paueksakon et al. 2002; Huang et al. 2008) . Besides diabetes, increased deposition of PAI-1 in the kidney has been demonstrated in most other human kidney diseases (Rondeau et al. 1990; Shihab et al. 1995; Yamamoto et al. 1996 Yamamoto et al. , 1999 Grandaliano et al. 2000; Lee et al. 2001) . The elevated expression of PAI-1 is found in podocytes, in endothelial and mesangial cells of the glomeruli, in proximal tubular epithelial cells and in small arteries and fibroblast cells in the interstitium (Keeton et al. 1993) . Importantly, genetic PAI-1 deficiency has been shown to be protective in experimental diabetic nephropathy, five-sixth nephrectomy, crescentic anti-GBM nephritis and the spontaneous renal fibrosis that develops in mice that overexpress transforming growth factor-β (TGFβ; Oda et al. 2001; Krag et al. 2005; Nicholas et al. 2005; Eddy & Fogo, 2006) . In contrast, the renal fibrosis is worse in PAI-1-overexpressing mice (Matsuo et al. 2005) . Together, these observations strongly implicate tissue PAI-1 in the renal fibrotic process.
The profibrotic actions of PAI-1 have not been completely elucidated. Plasminogen activator inhibitor type 1 possesses two distinct functions that could mediate its profibrotic effects alone or in combination, which are an antiprotease activity that inhibits the generation of plasmin and a vitronectin-binding ability that interferes with cell adhesion to this extracellular matrix protein . As the primary physiological inhibitor of urokinase (uPA) and tissue-type plasminogen activator, PAI-1 controls the formation and activity of plasmin and, consequently, promotes fibrin deposits and accumulation of fibrotic matrix.
The binding of PAI-1 to vitronectin could also be important in the pathogenesis of fibrosis. When bound to vitronectin, the antiprotease activity of PAI-1 is significantly stabilized (Podor et al. 2000) . The binding of PAI-1 to vitronectin also blocks the interactions of vitronectin with cell-surface integrin required for cellular motility and with the receptor for cell-bound uPA (uPAR). Furthermore, the binding of PAI-1 to vitronectin induces epithelial-to-mesenchymal transition in epithelial cells by modulating their interaction with the extracellular matrix, a process that is involved in tissue fibrosis (Scaffidi et al. 2001; Vial & McKeown-Longo, 2008; Senoo et al. 2010) . Whether the properties of PAI-1 observed in vitro are also operative in diseased subjects or animal models remains unclear.
In order to understand the actions of PAI-1 further and to develop a potential therapeutic agent that inhibits PAI-1 in vivo, a non-inhibitory mutant PAI-1 (PAI-1R) was designed (Stefansson et al. 2001) . This PAI-1R mutant does not inhibit uPA or tissue-type plasminogen activator, but it retains the ability to bind vitronectin, thereby decreasing the availability of vitronectin for PAI-1 and effectively shortening its half-life. The administration of PAI-1R to nephritic rats and diabetic db/db mice increased glomerular plasmin generation and reduced proteinuria and glomerulosclerosis . Using the plasminogen/plasmin blocker tranexamic acid, we further observed that the therapeutic effect of PAI-1R on glomerular extracellular matrix accumulation was largely mediated through plasmin, because this effect was blocked by cotreatment with tranexamic acid (Huang et al. 2006) .
However, the effect of PAI-1R on the reduction of proteinuria was not affected by blocking plasmin generation, suggesting that PAI-1R has multiple therapeutic actions on the measures of disease severity. Conversely, elevated PAI-1 may have multiple actions on the induction and progression of kidney disease. It is likely that PAI-1 may act as a direct cause of proteinuria independent of plasmin generation, which could be prevented by inhibition of PAI-1. This notion was strengthened by the observations that PAI-1 deletion significantly reduced the severity of proteinuria in diabetes (Nicholas et al. 2005; Collins et al. 2006; Lassila et al. 2007) . It has been shown that proteinuria is often the result of podocyte injury in human diseases and animal models, especially in diabetes (Yu et al. 2005; Shankland, J. Zhang and others 2006; Ziyadeh & Wolf, 2008) . Thus, we postulate that PAI-1 plays a role in podocyte injury and proteinuria. We further hypothesize that PAI-1R reduces proteinuria by the amelioration of podocyte injury via PAI-1 inhibition.
To test our hypothesis, we examined whether PAI-1 directly damaged podocytes in cell culture and determined the therapeutic efficacy of PAI-1R on podocyte injury in a murine model of uninephrectomized diabetic nephropathy.
Methods

Reagents
Unless otherwise indicated, materials and chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA). The recombinant human PAI-1R and active stable PAI-1 have been described previously (Huang et al. 2009 ) and were purified as described (Kvassman & Shore, 1995 (NIH publication no. 85-23, revised 1996) . The experimental protocols were approved by the Animal Care Committee at the University of Utah. The db/db mice were determined to be diabetic by the vendor on the basis of the appearance of obesity at ß5 weeks of age and were demonstrated to be hyperglycaemic in our laboratory at week 7. Mice were subjected to right uninephrectomy under general anaesthesia induced by inhalation of 2.5% isoflurane through a complete anaesthesia system (VetEquip IMPAC6; VetEquip Inc., Pleasanton, CA, USA) at week 8 to hasten the development of diabetic nephropathy as described previously . The db/m mice were subjected to uninephrectomy at week 8 to serve as the operation control. Our previous work on model development showed that uninephrectomized diabetic db/db mice developed overt nephropathy by 18 weeks of age, and disease progression was remarkable between 18 and 22 weeks of age, determined by expansion of the mesangium and significant albuminuria . In the present study, this model was used to determine the impact of PAI-1R on podocyte injury from 20 to 22 weeks of age.
Experimental design. Groups of eight or nine uninephrectomized mice were assigned and treated at 20 weeks of age as follows: untreated non-diabetic db/m mice (n = 9) as healthy control animals; diabetic db/db mice treated with PBS by I.P. injection from week 20 to 22 (n = 8) as disease control animals; and diabetic db/db mice treated with 0.5 mg (kg body weight) −1 PAI-1R injected I.P., twice daily, from week 20 to 22 (n = 8; the effective dose of PAI-1R was determined previously, see Huang et al. 2008) . The blood glucose level and glycosylated haemoglobin (HbA 1c ) level were monitored in tail blood samples by using a blood glucose metre (Glucometer Elite XL; Bayer Healthcare, Elkhart, IN, USA) and the DC 2000+ HbA1C kit (Bayer Healthcare), respectively. Collection of urine for 24 h was carried out for each mouse after placement in metabolic cages. Urine albumin was measured using the DC2000+ microalbumin reagent kit (Bayer Healthcare). Regarding the reproducibility of this assay, the coefficients of variance were <3% when the same sample was measured three times consecutively. Mice were killed under isoflurane anaesthesia in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. Briefly, general anaesthesia was induced by inhalation of 2.5% isoflurane through a complete anaesthesia system (VetEquip IMPAC6; VetEquip Inc., Pleasanton, CA, USA). When mice were deeply anaesthetized as determined by absence of the toe-pinch reflex, blood samples were obtained by cardiac puncture, and the kidneys were perfused through the heart with cold PBS and then excised. Mice died of massive blood loss. The renal cortex was harvested by dissection and saved for further analysis as described previously . Briefly, three pieces of cortex were either snap-frozen in 2-methylbutane at -80°C or fixed in 10% neutral-buffered formalin for immunohistological examination or fixed in 2.5% glutaraledhyde and 0.1 M sodium cacodylate buffer at 4°C for electron microscopic examination. Other pieces of cortex were treated with TRIzol TM Reagent (GibcoBRL, Gaithersburg, MD, USA) for isolation of RNA or treated with 100 mM NaCl and 20 mM Hepes to be sonicated for 30 s, three times on ice and centrifuged at 13,100 g for 15 min at 4°C. The supernatant from the sonication was then collected and stored at -80°C for fibronectin (FN) ELISA and protein measurement by a BCA protein assay kit (Pierce, Rockford IL, USA). The total collagen level in renal cortex was determined by a colorimetric method according to the manufacturer's instructions (Biocolor Ltd, Carrickfergus, UK), in which the Sirius Red dye binds to the side-chains of amino acids found in collagen.
Histological analyses. Formalin-fixed renal cortex tissues were subsequently embedded in paraffin. Three-micrometre-thick sections were cut from the tissue blocks and stained with periodic acid-Schiff. The periodic acid-Schiff-positive glomerular matrix was quantified in a blinded fashion by a computer-assisted method as previously described . At least 20 glomeruli from each mouse were assessed. The matrix surface area in the mesangium was normalized by that of the total glomerular tuft, where the percentage of mesangial matrix occupying each glomerulus was rated on a 0-4 scale (0 = 0, 1 = 25, 2 = 50, 3 = 75 or 4 = 100%), as described previously .
Immunofluorescent staining for nephrin and podocin was performed on frozen sections. The polyclonal goat anti-nephrin IgG and the polyclonal goat anti-podocin IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were used as the primary antibodies. The rhodamine (TRITC)-conjugated donkey anti-goat IgG (reacts with both heavy and light chains; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) was used as the secondary antibody. Intraglomerular positive staining of both molecules was also quantified separately in a blinded fashion by a computer-assisted method. Briefly, images (×400 magnification) of 20 random glomeruli per slide were captured using a Nikon D50 digital camera (Inkle's-Ritz Camera, www.ritzcamera.com, Salt Lake City, UT, USA; Nikon Capture 4 version 4.3, Nikon Inc., Melville, NY, USA), and the total staining intensity in each glomerulus was quantified using a computer-assisted colour image analysis system (ImageJ 1.38 for Windows; National Institutes of Health http://rsb.info.nih.gov; Abramoff et al. 2004) . The results were expressed as the ratio of the staining intensity in the experimental groups to that in the normal glomeruli.
Transmission electron microscopic examination. Glutaraledhyde-fixed renal cortex tissues were further processed with OsO 4 and Epon 812. Ultrathin sections were cut and stained with uranyl acetate and lead citrate. Specimens were placed on copper grids and examined in an electron microscope (JEOL JEM-1010, Tokyo, Japan). Foot-process density was calculated by dividing the number of foot processes by the glomerular basement membrane (GBM) length (Zheng et al. 2008) .
Western blot analysis. Equal amounts of renal cortex tissue (15 mg) from each mouse of each group were homogenized in lysis buffer (Cell Signaling Technology, Inc., Beverly, MA, USA) with 1% octylphenoxypolyethoxyethanol (Nonidet P-40), 1 mM phenylmethylsulfonyl fluoride and one tablet per 5 ml protease inhibitor mix (Complete, Mini; Roche Diagnostics Corporation, Indianapolis, IN, USA). Protein samples from eight or nine mice of each group were pooled for further examination.
For Western blot analysis, protein samples (20 μg each) were subjected to SDS-PAGE in 4-12% gradient gels (Invitrogen, Carlsbad, CA, USA) and immunblotted onto immobilon-P transfer membranes (Millipore Corporation, Bedford, MA, USA). Desmin and B7-1 were assessed on the Western blots using mouse monoclonal anti-desmin IgG2a (Santa Cruz Biotechnology, Inc.) and rabbit monoclonal anti-B7-1/CD80 IgG (OriGene Technologies, Inc., Rockville, MD, USA). The immunostaining band was visualized and quantified as described previously . Desmin and B7-1 protein levels were corrected by the densitometric intensity of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH; using goat anti-GAPDH IgG antibody; GenScript, Piscataway, NJ, USA) or β-actin (using mouse monoclonal anti-β-actin IgG) in each loading. For comparison, this ratio was set at unity for normal control samples, and other lanes on the same gel were expressed as the fold-change over this value. Three blots were performed for each primary antibody.
Preparation of RNA and real-time RT-PCR. Total RNA was extracted from renal cortex tissue using TRIzol TM Reagent (GibcoBRL) according to the manufacturer's instructions. Two micrograms of total RNA were reverse transcribed using the Superscript III first-strand synthesis system for RT-PCR kit (Invitrogen). Real-time RT-PCR was performed using the SYBR green dye I (Applied Biosystems, Foster City, CA, USA) and the ABI 7900 Sequence Detection System (Applied Biosystems) as described previously . Samples were run in triplicate in separate tubes to permit quantification of the target gene normalized to β-actin. Sequences of primers used are listed in Table 1 . The specificity of the PCR products was confirmed on a 1.5% agarose gel by showing a specific single band with the expected size.
Study 2: effect of wild-type PAI-I on cultured podocytes
Cell culture. Conditionally immortalized mouse podocytes were kindly provided by Dr Peter Mundel (Massachusetts General Hospital and Harvard Medical School). These cells were cultured and induced to differentiate as described previously (Reiser et al. 2004) . Briefly, podocytes were cultured in permissive conditions (33°C) in RPMI-1640 supplemented with 10% fetal calf serum, penicillin-streptomycin and interferon-γ (all from Invitrogen). Differentiation was induced by thermoshift to 37°C without interferon-γ in type I collagen-coated six-well plates (Fisher Science Education, Hanover Park, IL, USA) before experimental treatment. All experiments were performed with cells that had been allowed to differentiate for at least 14 days. Podocytes between passages 10 and 15 were used for all experiments.
J. Zhang and others Effect of PAI-1 on podocyte injury. To examine the effect of PAI-1 on podocyte injury, differentiated podocytes were rendered quiescence in serum-free medium for 24 h, then incubated with 150 nM of recombinant active stable human PAI-1 for various times or incubated for 24 h in incremental concentrations of PAI-1 (Huang et al. 2009 ). Podocytes treated with serum-free medium only or with 2 ng ml −1 TGFβ1 (R&D, Minneapolis, MN, USA) for 24 h served as normal and positive controls, respectively. After incubation, the podocytes were washed with ice-cold PBS. Total cellular RNA or protein was isolated from the podocytes as described previously for the analyses of the mRNA and protein expression of podocyte-associated molecules by real-time RT-PCR and Western blotting respectively . The rabbit polyclonal anti-nephrin antibody (TA306037) and rabbit polyclonal anti-zonula occludin-1 (ZO-1) antibody (61-7300) were obtained from OriGene Technologies and Invitrogen, respectively. All experiments were performed at least three times in duplicate wells.
Statistical analyses
Data are expressed as means ± SD. The disease-induced increase in a variable was defined as the mean value for the disease control group minus the mean value of the normal control group. The percentage of reduction in disease severity in a treated group was calculated as described previously . Statistical analyses of differences between the groups were performed by one-way ANOVA and subsequent Student-Newman-Keuls or Dunnett testing for multiple comparisons. A value of P < 0.05 was considered statistically significant.
Results
Study 1: therapeutic efficacy of PAI-1R
Systemic parameters. There was no significant difference in survival rate among the groups of non-diabetic db/m mice, diabetic db/db mice treated with PBS and diabetic db/db mice treated with PAI-1R. The baseline and final parameters of the three groups of mice are presented in Table 2 . The body weights of db/db mice at 20 weeks of age were significantly greater than the corresponding values in db/m control animals. There was no significantly change in body weight from week 20 to 22 in db/db mice. Diabetic mice remained hyperglycaemic throughout the experimental period, as indicated by blood glucose and glycosylated haemoglobin levels. The PAI-1R treatment had no effect on body weight or blood glucose levels in the db/db mice.
At the beginning of intervention (20 weeks of age), urinary albumin excretion of db/db mice in both groups treated with or without PAI-1R was similar and was significantly higher compared with db/m mice. Albumin excretion stayed high between weeks 20 and 22 in PBS-treated db/db mice. The PAI-1R treatment, in fact, lowered the urinary albumin excretion by 31.4% (359.5 ± 45.3 versus 247.4 ± 19.1 μg day −1 ; P < 0.05).
Glomerular histology. At the end of the study (22 weeks), the glomeruli of db/db mice demonstrated increased accumulation of periodic acid-Schiff-positive extracellular matrix proteins in the mesangium, compared with glomeruli of db/m mice ( Fig. 1A and B) . Treatment with PAI-1R ameliorated extracellular matrix deposition from the diabetic glomeruli by 36.3% (P < 0.05).
Collagen and FN levels in renal cortex. The levels of both collagen and FN, two major components of glomerular extracellular matrix, were quantified in the renal cortex. Consistent with the accumulation of glomerular periodic acid-Schiff-positive extracellular matrix, levels of FN and collagen were significantly increased in db/db mice at week 22. The PAI-1R treatment reduced the disease-induced increases in protein levels of FN and collagen by 62.5 and 67.7%, respectively (P < 0.05; Fig. 1C and D). Electronic microscopy of podocyte ultrastructure. As shown in Fig. 2A -C, segmental podocyte foot-process effacement and a decrease in foot-process density were evident in the glomeruli from diabetic mice at 22 weeks, in comparison to glomeruli from non-diabetic mice (db/db versus db/m, 1.56 ± 0.35 versus 3.42 ± 0.34, P < 0.05). The PAI-1R treatment effectively restored foot-process density (PAI-1R versus db/db, 2.83 ± 0.67 versus 1.56 ± 0.35, P < 0.05). The changes of the podocyte foot process can be seen clearly in the high-resolution images ( Fig. 2D-F) . 
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Expression of podocyte slit-diaphragm-associated
proteins. In order to confirm the protective effects of PAI-1R on podocyte injuries observed using electronic microscopy, the podocyte slit-diaphragm-associated proteins nephrin and podocin were assessed by immunofluorescent staining. As shown in Fig. 3 , nondiabetic db/m mice showed intense and linear staining for both nephrin and podocin along the capillary in the glomeruli. In contrast, diabetes resulted in an attenuation of staining by 48.4% for nephrin and 36.9% for podocin (P < 0.05) in the glomeruli of db/db mice at 22 weeks of age. The administration of PAI-1R reduced the loss of podocyte-specific nephrin and podocin staining by 58.6 and 73.7%, respectively (P < 0.05). Expression of markers of podocyte injury. By Western blotting, we observed that the protein levels of desmin in renal cortex tissues, a conventional marker for podocyte injury, were upregulated by 190% in diabetic db/db mice (P < 0.05), as shown in Fig. 4 . The PAI-1R treatment reversed the disease-induced increase of desmin protein.
In addition, it has been shown that B7-1 is synthesized in podocytes in response to split-diaphragm protein rearrangement and foot-process effacement, and serves as another marker of injury (Reiser et al. 2004) . As shown in Fig. 4 , B7-1 protein levels were markedly increased in diabetic renal tissue in db/db mice. Although we could not confirm whether the elevated production of desmin and B7-1 was from podocytes, the changes of both desmin and B7-1 were consistent with the changes of the two slit-diaphragm-associated proteins nephrin and podocin shown in Fig. 3 , which may indicate that increased renal production of desminin and B7-1 could somehow be related to podocyte injury in diabetic db/db mice. Consistent with the results for nephrin and podocin, PAI-1R treatment also successfully reduced the elevated B7-1 protein expression in db/db mice by 58.3% (P < 0.05).
In agreement with protein levels, over 50% mRNA expression of nephrin was lost in diabetic db/db mice at week 22, compared with that of db/m control animals. The PAI-1R treatment rescued 71.5% of the reduction of nephrin mRNA levels in diabetic renal tissue (Fig. 5A) . 
PAI-1R
Nephrin ZO-1 
J. Zhang and others
In contrast, mRNA expression of desmin and B7-1 was markedly increased in diabetic renal tissue by 14-and 20-fold, respectively (P < 0.05), compared with that found in normal renal tissue (P < 0.05). The PAI-1R treatment reversed the increased mRNA expression of desmin and B7-1 (Fig. 5C and D) , similar to the response of the corresponding proteins. We also measured mRNA expression of the tight junction protein ZO-1 in podocytes. Unsurprisingly, ZO-1 mRNA was 68.6% lower in diabetic renal tissues than in normal control tissues (P < 0.05). This reduction in ZO-1 expression was completely reversed by PAI-1R treatment (P < 0.05; Fig. 5B ). Collectively, these data suggest that PAI-1R treatment protects podocyte integrity in diabetic db/db mice by preserving the expression of slit-diaphram proteins and counter-regulating pathogenic molecules involved in podocyte injury.
Study 2: direct effect of PAI-1 on podocyte injury in vitro
Effect of PAI-1 on mRNA expression of nephrin, ZO-1, desmin and B7-1 by podocytes. It has been shown that the therapeutic efficacy of PAI-1R is largely due to its ability to reduce endogenous activity of PAI-1, by competion for binding to vitronectin at the site of injury but lack of protease inhibitory activity (Huang et al. 2006 (Huang et al. , 2009 . In order to delineate the mechanism of action of PAI-1R further, we examined the direct effect of PAI-1 in a cultured podocyte model. Based on our previous studies on cultured mesangial cells (Huang et al. 2006) , a recombinant active stable human PAI-1 at the concentration of 150 nM was chosen. As shown in Fig. 6 , addition of PAI-1 to podocytes for up to 48 h caused a time-dependent inhibition of both nephrin and ZO-1 mRNA expression. The inhibition at 6 h was 13.4% for nephrin and 27.2% for ZO-1, and >80% (P < 0.05) at 48 h ( Fig. 6A and B) . Importantly, these changes seen in PAI-1-treated podocytes were similar to those observed in podocytes exposed to 2 ng ml −1 TGFβ1 for 24 h. The 24 h time point was thus used for further experiments as described below.
A dose-dependent decrease in mRNA levels of both nephrin and ZO-1 (P < 0.05; Fig. 7A and B) and a dose-dependent increase in mRNA levels of B7-1 (P < 0.05; Fig. 7D ) in podocytes were seen after 24 h of treatment with PAI-1. While there was also an increase in mRNA levels of desmin with PAI-1 treatment, the dose dependence of this phenomenon was less apparent (Fig. 7C) , In comparison, the addition of 2 ng ml −1
TGFβ1 to podocytes for 24 h resulted in dramatic decreases in both nephrin and ZO-1 mRNA expression and dramatic increases in both desmin and B7-1 mRNA expression (P < 0.05 versus normal control for each comparison). These data indicate that PAI-1 directly alters gene expression of podocyte molecules in a manner similar to TGFβ1.
Effect of PAI-1 on protein production of nephrin, ZO-1 and B7-1 by podocytes. Consistent with the results on mRNA expression, 150 nM PAI-1 and 2 ng ml −1 TGFβ1 decreased the protein levels of nephrin and ZO-1 (by 39.4 and 45.4% for nephrin and 18.7 and 32.0% for ZO-1, respectively; all P < 0.05; Fig. 8 ). Meanwhile, both PAI-1 and TGFβ1 significantly increased B7-1 protein production by 230 and 246%, respectively. These results indicate that PAI-1, similar to TGFβ1, induces podocyte injury by altering the protein production of normal slit-diaphram molecules and B7-1.
Discussion
In the present experiments, we repeatedly observed that uninephrectomized, diabetic db/db mice developed overt nephropathy associated with progressive albuminuria and glomerular mesangial matrix expansion and increased renal production of fibronectin and collagen at 22 weeks of age. Treatment with human PAI-1R from week 20 to 22 had no effect on body weight, plasma glucose and HbA 1c levels but reduced albuminuria and markers of renal fibrosis seen in db/db mice. Although we have not dissected the plasmin-dependent and plasmin-independent actions of PAI-R in the db/db mouse model, we have previously shown that the effects of PAI-1R on pathological matrix accumulation in the model of anti-thy-1 nephritis were completely reversed by tranexamic acid treatment (Huang et al. , 2006 , indicating the plasmin dependence of these therapeutic actions. In contrast, tranexamic acid had no effect on other disease measures, including proteinuria, in an anti-thy-1 nephritis model with PAI-1R treatment (Huang et al. 2006) . This latter observation suggests that PAI-1R has other actions in addition to enhancing plasmin generation.
Increasing evidence shows that the development of proteinuria is typically associated with podocyte foot-process effacement and/or slit-diaphragm disruption in proteinuric kidney diseases, including diabetic nephropathy (Fornoni, 2010) . Consistent with this notion, untreated diabetic db/db mice in the present study developed significant segmental podocyte foot-process effacement associated with reduced renal production of nephrin, podocin and ZO-1 and increased renal production of B7-1 and desmin. Importantly, these changes in podocyte morphology and protein molecules that are indicative of podocyte injury were all ameliorated by the treatment with PAI-1R. Nephrin and podocin are critical for maintaining the barrier function of the podocyte slit-diaphragm (Liu et al. 2003; Kawachi et al. 2006) . Dysfunction or loss of nephrin and podocin may cause changes in podocyte shape, such as foot-process effacement, and attenuate the contractile function of podocytes, leading to detachment from the underlying GBM (Liu et al. 2003; Kawachi et al. 2006) . The PAI-1R treatment may therefore reduce podocyte injury by preserving the normal structure of podocyte foot processes and slit-diaphragms.
B7-1 is a transmembrane protein normally expressed on the surface of B lymphocytes and antigen-presenting cells (Abbas & Sharpe, 1999; Chambers & Allison, 1999) . It has been demonstrated to be synthesized de novo in podocytes and involved in the disruption of the slit-diaphragm protein complex and the induction of foot-process effacement in response to a variety of stress conditions (Reiser et al. 2004) . Thus, B7-1 also acts as an autocrine factor to modulate podocyte integrity beyond its role in immune cells. Indeed, it has been shown that the mRNA expression of B7-1 in urinary sediments correlates with the severity of proteinuria in patients with kidney diseases (Navarro-Muñoz et al. 2011) . We observed that the mRNA expression and protein production of B7-1 were significantly increased in diabetes in the present study (Figs 4 and 5) . However, PAI-1R treatment substantially reversed the diabetes-induced elevation of B7-1, which was accompanied by the recovery of podocyte morphology and slit-diaphragm protein production and a reduction in albuminuria.
In addition, podocyte epithelial-to-mesenchymal transition, characterized by the loss of epithelial markers, such as ZO-1, and gain of mesenchymal markers, such as desmin, has been involved in podocyte foot-process effacement Yamaguchi et al. 2009 ). In the present study, we also observed a reduction in ZO-1 and an increase in desmin in diabetic renal tissue in db/db mice at 22 weeks of age. Treatment with PAI-1R largely reversed these changes in the signalling molecules of podocyte epithelial-to-mesenchymal transition. Together, these results provide evidence that PAI-1R protects the podocyte from injury by counter-regulating the expression profile of slit-diaphragm proteins and pathogenic molecules in db/db mice. Consequently, podocyte protection may be quantified as a marked reduction in albuminuria in the db/db mice (Table 2 ).
In concordance with the protective effect of PAI-1R on podocyte injury is the notion that PAI-1 directly regulates podocyte protein expression resulting in cellular injury and proteinuria. Notably, PAI-1 deletion prevented diabetic renal complications, including albuminuria, in both db/db diabetic mice and streptozotocin-induced diabetic mice (Nicholas et al. 2005; Collins et al. 2006; Lassila et al. 2007) , while transgenic overexpression of PAI-1 exaggerated proteinuria in a model of immune nephritis (Kitching et al. 2003) , although podocyte structures were not examined in those animals. In a mouse model of angiotensin II-mediated hypertensive kidney disease (Knier et al. 2011) , the knockout of PAI-1 resulted in less glomerulosclerosis. Coincidentally, more intense nephrin immunostaining was found in the podocytes. Our present observation in cultured podocytes provides the first evidence that PAI-1 directly induces podocyte injury by altering the expression of nephrin and B7-1, similar to the actions of TGFβ1 (Figs 6-8) , a well-known mediator of podocyte injury (Reiser et al. 2004) . In addition, PAI-1 appeared to be sufficient to induce podocyte epithelial-to-mesenchymal transition in cell culture by changing the cellular expression of ZO-1 and desmin, similar to the effects of TGFβ1. Collectively, these observations suggest a new mechanism for the role of PAI-1 in the pathogenesis of kidney disease via induction of podocyte injury, in addition to the known injurious effects of PAI-1 on the matrix degradation (Huang et al. 2006 ). The signalling pathway by which PAI-1 directly modulates podocyte-associated molecules is unclear. A new signalling pathway in podoctyes that involves vitronectin, uPAR and α v β 3 integrin has recently been identified, which leads to podocyte foot-process effacement and urinary protein loss (Wei et al. 2008) . These findings, together with the ability of PAI-1 to bind to vitronectin and complex with uPAR through PAI-1 complex formation with uPA, have led to the exciting possibility that PAI-1 induces podocyte injury through activation of this uPAR signalling pathway. This further suggests that the plasmin-independent benefit of PAI-1R may stem from its inability to interact stably with uPAR, and thus not activate this signalling pathway.
In conclusion, the present study provides evidence that, similar to TGFβ1, PAI-1 directly injures podocytes in diabetes. Reducing the increased PAI-1 activity by treatment with PAI-1R may, in fact, reduce podocyte injury, thereby reducing albuminuria. Therefore, PAI-1R may provide additional therapeutic effect in slowing the progression of diabetic nephropathy by maintaining podocyte integrity.
